Sensei Biotherapeutics (NASDAQ:FTH) Receives Buy Rating from BTIG Research

BTIG Research reaffirmed their buy rating on shares of Sensei Biotherapeutics (NASDAQ:FTH) in a research report released on Thursday morning,Benzinga reports. They currently have a $55.00 target price on the stock.

Other equities analysts also recently issued reports about the stock. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They issued an “outperform” rating and a $57.00 price target on the stock. Wall Street Zen cut shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings initiated coverage on shares of Sensei Biotherapeutics in a report on Wednesday, June 17th. They issued a “sell (d-)” rating for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Finally, Citigroup started coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They set a “buy” rating and a $55.00 target price on the stock. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $54.50.

Sensei Biotherapeutics Stock Performance

Shares of FTH opened at $25.94 on Thursday. The stock has a market capitalization of $34.76 million, a PE ratio of -0.18 and a beta of -0.26. Sensei Biotherapeutics has a fifty-two week low of $6.32 and a fifty-two week high of $37.90.

Sensei Biotherapeutics (NASDAQ:FTH) last posted its earnings results on Friday, May 15th. The company reported ($131.45) earnings per share (EPS) for the quarter. Equities research analysts anticipate that Sensei Biotherapeutics will post -16.61 EPS for the current fiscal year.

Insider Buying and Selling at Sensei Biotherapeutics

In other Sensei Biotherapeutics news, CFO Brian C. Stephenson acquired 9,391 shares of the company’s stock in a transaction that occurred on Wednesday, June 24th. The stock was acquired at an average price of $26.13 per share, for a total transaction of $245,386.83. Following the acquisition, the chief financial officer directly owned 26,804 shares in the company, valued at $700,388.52. This represents a 53.93% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder James Peyer sold 25,000 shares of Sensei Biotherapeutics stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total transaction of $500,500.00. Following the sale, the insider owned 130,142 shares in the company, valued at approximately $2,605,442.84. This represents a 16.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have acquired a total of 49,494 shares of company stock worth $1,188,822 over the last 90 days. Insiders own 7.00% of the company’s stock.

Institutional Trading of Sensei Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC boosted its position in shares of Sensei Biotherapeutics by 10.6% during the 4th quarter. Renaissance Technologies LLC now owns 11,516 shares of the company’s stock valued at $123,000 after purchasing an additional 1,100 shares in the last quarter. Bank of America Corp DE boosted its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after buying an additional 32,719 shares during the last quarter. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth approximately $4,188,000. Finally, Vivo Capital LLC purchased a new position in shares of Sensei Biotherapeutics during the 1st quarter valued at $22,758,000. 10.50% of the stock is currently owned by institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.